Library›Substances and pharmacology›L-Arginine

L-Arginine

L-Arginine is the substrate from which nitric oxide is made, and the clearest case in the Institute's stack of a supplement whose oral form is the wrong form.

What it does

Arginine is a semi-essential amino acid and the sole nitrogen donor for nitric oxide synthase (NOS), which converts it to nitric oxide and citrulline. Nitric oxide is the endothelium's vasodilator signal; declining endothelial NO output is one of the better-characterised features of vascular ageing. Arginine is also a precursor for creatine, urea, ornithine, polyamines and proline, which puts it upstream of collagen as well.

The first-pass problem

Oral arginine is extensively degraded before it reaches circulation. Intestinal and hepatic arginase consumes much of a dose on the way through, so plasma arginine rises far less than the label implies and the effect is dose-limited by gastrointestinal upset before it is limited by anything useful.

Citrulline raises plasma arginine more reliably than arginine does. Citrulline escapes first-pass arginase entirely and is converted to arginine in the kidney. This is the same lesson as folate versus L-methylfolate and iron sulphate versus chelate: the molecule on the label is not the molecule that arrives. The Institute's 2021 post used an arginine/citrulline blend for this reason before the pharmacology was written up.

The BH4 coupling — why it sits beside the folate

NOS is a BH4-dependent enzyme, and this is the point of taking arginine in this stack rather than on its own.

When BH4 is scarce relative to substrate, NOS uncouples: instead of producing nitric oxide it produces superoxide, becoming a source of the oxidative stress it is supposed to oppose. Supplying more arginine to an uncoupled enzyme does not produce more NO. It produces more radical.

So arginine and L-methylfolate are not two independent entries in a list. The folate keeps the cofactor regenerated so that the substrate has somewhere to go. This is The Amplification Framework in its plainest form — substrate, cofactor, and the protection of the cofactor — and it is why vitamin C and carnosine belong in the same stack.

ADMA (asymmetric dimethylarginine), an endogenous NOS inhibitor that accumulates in renal and cardiovascular disease, competes at the same site and is the reason arginine's clinical results are inconsistent across populations.

Cautions

• After myocardial infarction — the VINTAGE MI trial found higher mortality in the arginine arm among post-infarct patients. This is the single most important warning on the molecule and it is not a theoretical one.
• Herpes simplex — arginine supports viral replication and lysine opposes it. People with frequent HSV recurrences often react badly to arginine loading.
• Hypotension — additive with antihypertensives, nitrates and PDE5 inhibitors.
• Asthma — arginine metabolism is altered in asthmatic airways; evidence is mixed and caution is reasonable.
• Renal and hepatic impairment — arginine is handled by both organs.
• Gastrointestinal upset and osmotic diarrhoea are the usual practical dose limit.

See also: The Amplification Framework · L-Methylfolate · Amino Acid Complexes · Chelated Minerals · Stack Substances

Filed under  Substances and pharmacology